An Ionis Pharmaceuticals drug has preliminary data showing it met the main goal of its pivotal test in a rare disease with only a handful of approved treatments. With these results in hand, Ionis is ...
A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the ...
How Ionis Pharmaceuticals Stock Has Been Trading Ionis Pharmaceuticals (IONS) has drawn investor attention recently as the stock moved 2.3% in the latest session, with shorter term returns differing ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from ...
Biogen (BIIB) added ~9% in the premarket on Thursday after the company shared results from a mid-stage trial evaluating diranersen, an experimental therapy for Alzheimer’s disease developed in ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, ...
--Ionis Pharmaceuticals, Inc. today reported financial results for the third quarter of 2024.. We are similarly well positioned for our second independent launch for donidalorsen, which we believe ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Ionis Pharmaceuticals on Thursday won Food and Drug Administration approval of a ...
This is a new position for Capricorn Fund Managers Ltd, representing 3.58% of 13F reportable AUM as of September 30, 2025. Top holdings after the filing: WAY: $19.15 million (6.4% of AUM) as of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results